|
Tecentriq (atezolizumab)
|
|
Zometa (zoledronic acid) - risk of osteonecrosis of the jaw
|
|
L-Thyroxin Berlin-Chemie (levothyroxine) new formulation tablets: monitoring of patients switching between tablets
|
|
Therapy guide with Vsiqq (brolucizumab)
|
|
Actemra (tocilizumab)
|
|
Tecentriq (atezolizumab)
|
|
Direct Healthcare Professional Communication about Recormon (epoetin beta)
|
|
Novartis information on ophthalmic products based on Safety Notice provided by Becton Dickinson Company
|
|
Supply situation for Actemra IV - outlook for 2022
|
|
Kadcyla: Educational Information For Healthcare Professional
|
